SS
RARE icon

Steve Schonfeld’s Ultragenyx Pharmaceutical RARE Stock Holding History

Steve Schonfeld’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77M Sell
52,881
-441,856
-89% -$11M 0.01% 1135
2026
Q1 		$10.4M Sell
494,737
-246,881
-33% -$5.56M 0.07% 289
2025
Q4 		$17.1M Sell
741,618
-402,971
-35% -$13.3M 0.08% 231
2025
Q3 		$34.4M Buy
1,144,589
+577,414
+102% +$17.3M 0.2% 81
2025
Q2 		$20.6M Sell
567,175
-257,243
-31% -$9.27M 0.14% 152
2025
Q1 		$29.9M Buy
824,418
+76,989
+10% +$3.2M 0.18% 85
2024
Q4 		$31.4M Buy
747,429
+346,596
+86% +$17.2M 0.18% 83
2024
Q3 		$22.3M Sell
400,833
-316,114
-44% -$16.1M 0.15% 114
2024
Q2 		$29.5M Buy
716,947
+276,149
+63% +$11.8M 0.19% 99
2024
Q1 		$20.6M Buy
440,798
+97,986
+29% +$4.62M 0.14% 159
2023
Q4 		$16.4M Buy
+342,812
New +$13.3M 0.11% 209
2023
Q2 		– Sell
-19,474
Closed -$781K – 2435
2023
Q1 		$781K Buy
+19,474
New +$836K 0.01% 1031
2022
Q3 		– Sell
-21,348
Closed -$1.27M – 3132
2022
Q2 		$1.27M Buy
+21,348
New +$1.31M 0.01% 911
2021
Q4 		– Sell
-9,670
Closed -$872K – 2457
2021
Q3 		$872K Buy
9,670
+7,353
+317% +$665K 0.01% 1010
2021
Q2 		$221K Buy
+2,317
New +$241K ﹤0.01% 1622
2020
Q1 		– Sell
-6,545
Closed -$279K – 1452
2019
Q4 		$279K Buy
+6,545
New +$270K 0.01% 1012
2019
Q3 		– Sell
-13,900
Closed -$883K – 1199
2019
Q2 		$883K Sell
13,900
-3,800
-21% -$242K 0.03% 482
2019
Q1 		$1.23M Sell
17,700
-15,907
-47% -$909K 0.04% 452
2018
Q4 		$1.46M Sell
33,607
-2,593
-7% -$142K 0.06% 382
2018
Q3 		$2.76M Buy
+36,200
New +$2.94M 0.12% 227
2018
Q2 		– Sell
-40,050
Closed -$2.04M – 927
2018
Q1 		$2.04M Buy
+40,050
New +$2.02M 0.15% 197
2017
Q2 		– Sell
-4,337
Closed -$295K – 741
2017
Q1 		$295K Buy
+4,337
New +$331K 0.03% 474

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Steve Schonfeld's RARE Position: Q2 2026 in Review

Steve Schonfeld reduced its Ultragenyx Pharmaceutical (RARE) stake by 89% in Q2 2026, selling an estimated $11M and leaving 52,881 shares worth $1.77M. The position accounts for 0.01% of the portfolio, ranked #1135.

Steve Schonfeld first reported a position in RARE in Q1 2017 and has held it in 22 quarters since. The position peaked at $34.4M in Q3 2025. 308 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Steve Schonfeld held 52,881 shares of Ultragenyx Pharmaceutical worth $1.77M as of Q2 2026.
  • Steve Schonfeld sold 441,856 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $11M.
  • Ultragenyx Pharmaceutical made up 0.01% of Steve Schonfeld's portfolio in Q2 2026, its #1135 holding.
  • Steve Schonfeld first reported a position in Ultragenyx Pharmaceutical in Q1 2017 and has held it in 22 quarters since.
  • Steve Schonfeld's Ultragenyx Pharmaceutical position peaked at $34.4M in Q3 2025.
  • 308 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.